Diamedica Therapeutics Stock Cash Flow From Operations
| DMAC Stock | USD 4.67 0.15 3.11% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess DiaMedica Therapeutics' long-term financial health and intrinsic value.
DiaMedica | Cash Flow From Operations | Build AI portfolio with DiaMedica Stock |
DiaMedica Therapeutics Company Cash Flow From Operations Analysis
DiaMedica Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current DiaMedica Therapeutics Cash Flow From Operations | (22.08 M) |
Most of DiaMedica Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DiaMedica Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
DiaMedica Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for DiaMedica Therapeutics is extremely important. It helps to project a fair market value of DiaMedica Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since DiaMedica Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DiaMedica Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DiaMedica Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, DiaMedica Therapeutics has (22.08 Million) in Cash Flow From Operations. This is 104.19% lower than that of the Biotechnology sector and 135.31% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 102.27% higher than that of the company.
DiaMedica Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DiaMedica Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DiaMedica Therapeutics could also be used in its relative valuation, which is a method of valuing DiaMedica Therapeutics by comparing valuation metrics of similar companies.DiaMedica Therapeutics is currently under evaluation in cash flow from operations category among its peers.
DiaMedica Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of DiaMedica Therapeutics from analyzing DiaMedica Therapeutics' financial statements. These drivers represent accounts that assess DiaMedica Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of DiaMedica Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 159.0M | 77.5M | 41.8M | 219.4M | 252.3M | 132.5M | |
| Enterprise Value | 151.7M | 72.8M | 37.5M | 216.7M | 249.2M | 128.8M |
DiaMedica Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DiaMedica Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DiaMedica Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
DiaMedica Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 204.45 M | ||||
| Shares Outstanding | 51.49 M | ||||
| Shares Owned By Insiders | 30.80 % | ||||
| Shares Owned By Institutions | 43.34 % | ||||
| Number Of Shares Shorted | 2.41 M | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 7.08 X | ||||
| EBITDA | (24.38 M) | ||||
| Net Income | (24.44 M) | ||||
| Cash And Equivalents | 38.44 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 340 K | ||||
| Current Ratio | 25.50 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (22.08 M) | ||||
| Short Ratio | 6.95 X | ||||
| Earnings Per Share | (0.64) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 12.33 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 240.46 M | ||||
| Total Asset | 46.34 M | ||||
| Retained Earnings | (140 M) | ||||
| Working Capital | 39.22 M | ||||
| Current Asset | 5.24 M | ||||
| Current Liabilities | 1.05 M | ||||
| Net Asset | 46.34 M |
About DiaMedica Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DiaMedica Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DiaMedica Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DiaMedica Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out DiaMedica Therapeutics Piotroski F Score and DiaMedica Therapeutics Altman Z Score analysis. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.